set11 Antibody

What is SET11 Antibody and what are its primary research applications?

SET11 antibody can refer to either SOX11 or SETD1B antibodies, which are used in different research contexts. SOX11 antibody recognizes the SOX11 transcription factor that acts as a transcriptional activator and plays critical roles in neural development and organogenesis . SETD1B antibody targets a histone methyltransferase that catalyzes methyl group transfer to histone H3 at lysine 4 (H3K4), forming methylation marks at active chromatin sites .

For research applications, SOX11 antibody is typically used in studying neural tube development, neurogenesis, and certain malignancies where SOX11 is aberrantly expressed. The antibody can be applied in immunoprecipitation (IP), western blot (WB), and flow cytometry protocols . SETD1B antibody is primarily utilized in epigenetic research to study chromatin remodeling, transcriptional regulation, and hematopoietic lineage specification. Common applications include immunohistochemistry on paraffin-embedded sections (IHC-P) and immunoprecipitation (IP) .

How should researchers validate SET11 antibody specificity before experimental use?

Antibody validation is critical for ensuring experimental reproducibility and reliability. For SET11 antibodies, validation should follow a multi-step approach:

• Western blot analysis: Confirm the antibody detects a protein of expected molecular weight (SOX11 or SETD1B) in positive control samples. For instance, SOX11 antibody has been validated in human fetal brain tissue, SH-SY5Y cells, and Y79 cell lysates, while SETD1B antibody has been validated in HeLa whole cell lysate .

• Positive and negative controls: Include tissues or cell lines known to express the target protein (positive control) and those that don't (negative control). For SOX11, fetal brain tissue serves as a positive control .

• Immunoprecipitation validation: Verify that the antibody can successfully pull down the target protein from cell lysates. The IP results should be confirmed by western blot analysis .

• Cross-reactivity testing: Test for cross-reactivity with related proteins, particularly those with similar structural domains (other SOX family members or other SET domain proteins).

• Knockdown or knockout validation: Use samples from knockdown/knockout systems to confirm antibody specificity where feasible.

Thorough validation ensures that experimental findings accurately reflect the biology of the target protein rather than artifacts of non-specific binding .

What are the optimal buffer conditions and sample preparation methods for SET11 antibody-based experiments?

Optimal conditions for SET11 antibody experiments vary by application and specific antibody target:

For SOX11 antibody:

• Western blotting: Use standard RIPA or NP-40 lysis buffers with protease inhibitors. Sample dilution of 1/1000 is recommended with 10 μg of protein lysate per lane .

• Flow cytometry: Use 0.1% saponin in PBS for permeabilization and 1-2% BSA in PBS as blocking reagent .

• Fixation: Paraformaldehyde (4%) works well for most applications.

For SETD1B antibody:

• Immunohistochemistry: Use formalin/PFA-fixed paraffin-embedded sections with a recommended dilution of 1/1000 (1μg/ml) .

• Immunoprecipitation: 10 μg of antibody per mg of cell lysate has shown good results with HeLa whole cell lysate .

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is recommended for IHC applications.

For both antibodies, samples should be prepared fresh when possible, or properly stored with protease and phosphatase inhibitors to preserve protein integrity. Cell lysis should be performed at 4°C to minimize protein degradation, and multiple freeze-thaw cycles should be avoided .

How do SOX11 and SETD1B antibodies differ in their detection mechanisms and epitope recognition?

SOX11 and SETD1B antibodies recognize different epitopes and employ different detection mechanisms:

SOX11 antibody (EPR8191(2)):

• Recognizes epitopes within the SOX11 transcription factor

• Generated as a rabbit recombinant monoclonal antibody, providing high specificity and batch-to-batch consistency

• Detects SOX11 primarily in the nucleus where it functions as a transcription factor

• Western blot shows a characteristic band at the expected molecular weight

SETD1B antibody (ab113984):

• Recognizes a synthetic peptide within human SETD1B amino acids 350-400

• Produced as a rabbit polyclonal antibody, offering potential advantage in recognizing multiple epitopes

• Targets SETD1B (also known as KMT2G), a histone methyltransferase found primarily in chromatin-associated complexes

• Expected to detect a protein of approximately 209 kDa

The difference in antibody format (monoclonal vs. polyclonal) impacts their application. Monoclonal antibodies like the SOX11 antibody provide highly specific recognition of a single epitope, while polyclonal antibodies like the SETD1B antibody recognize multiple epitopes, potentially offering higher sensitivity but with potential for increased background .

What are the key considerations when optimizing immunoprecipitation protocols using SET11 antibodies?

Successfully optimizing immunoprecipitation (IP) protocols with SET11 antibodies requires attention to several critical parameters:

Antibody amount optimization:

• For SETD1B antibody, 10 μg per mg of lysate has been validated for successful IP

• For SOX11 antibody, titration experiments should be performed to determine optimal antibody:lysate ratio

Lysis buffer selection:

• Use non-denaturing buffers that preserve protein-protein interactions if studying complexes

• For chromatin-associated proteins like SETD1B, consider specialized nuclear extraction protocols

• Include protease/phosphatase inhibitors and DNase/RNase if necessary

Pre-clearing strategy:

• Pre-clear lysate with control IgG and protein A/G beads to reduce non-specific binding

• This step is particularly important when working with polyclonal antibodies

Washing stringency:

• Balance between maintaining specific interactions and removing background

• Typically start with low-stringency buffers and increase salt concentration in subsequent washes

• For SOX11 or SETD1B IPs, at least 3-5 washes are recommended

Elution method:

• Consider gentle elution methods if planning downstream functional assays

• SDS-based elution is suitable for western blot analysis

Controls:

• Always include IgG isotype controls processed identically to experimental samples

• Consider input controls (5-10% of starting material) for normalization

A successful IP protocol should be validated by western blot analysis showing enrichment of the target protein in the IP fraction compared to input and absence in the IgG control .

How can SET11 antibodies be employed in chromatin immunoprecipitation (ChIP) studies for transcriptional regulation research?

SET11 antibodies, particularly those targeting SETD1B, can be valuable tools in ChIP studies to understand transcriptional regulation mechanisms:

ChIP protocol adaptations for SETD1B:

• Crosslinking optimization: Since SETD1B is a histone methyltransferase that interacts with chromatin, dual crosslinking with both formaldehyde (1%) and ethylene glycol bis(succinimidyl succinate) (EGS) may improve recovery of protein-DNA complexes.

• Sonication parameters: Chromatin should be sheared to 200-500 bp fragments, with optimization required for different cell types and equipment.

• Antibody amount: Typically 5-10 μg of SETD1B antibody per ChIP reaction, though this should be empirically determined.

• Bead selection: Protein A beads are recommended for rabbit polyclonal antibodies like the SETD1B antibody.

• Washing stringency: Include high-salt washes to reduce background while preserving specific SETD1B-chromatin interactions.

Expected outcomes with SETD1B ChIP:

• Enrichment at active promoters and enhancers, particularly those with H3K4 methylation marks

• Co-localization with other components of the MLL/SET1 methyltransferase complex

• Detection at sites of active transcription and DNA repair

Data analysis considerations:

• Normalization to input DNA and IgG control is essential

• Integration with H3K4me1/2/3 ChIP data provides functional context

• Correlation with transcriptomic data helps interpret biological significance

ChIP-seq studies using SETD1B antibodies can provide genome-wide maps of SETD1B binding, offering insights into its role in chromatin remodeling and transcriptional regulation in different cellular contexts .

What approaches should be taken when troubleshooting non-specific binding or high background with SET11 antibodies?

Non-specific binding and high background are common challenges when working with antibodies. For SET11 antibodies, consider the following troubleshooting approaches:

For SOX11 antibody specifically, validate that the observed signal disappears in tissues known to lack SOX11 expression. The recombinant monoclonal format (EPR8191(2)) should provide high specificity, but titration is still recommended .

For SETD1B antibody (polyclonal), higher background is more likely due to the nature of polyclonal antibodies. Consider additional blocking steps and more stringent washing conditions. Validation with siRNA knockdown of SETD1B can confirm specificity .

In both cases, peptide competition assays, where the antibody is pre-incubated with excess immunizing peptide, can help identify non-specific binding .

How can researchers quantitatively analyze SET11 protein expression levels across different experimental conditions?

Quantitative analysis of SET11 protein expression requires rigorous standardization and appropriate controls. The following methodological approaches are recommended:

Western Blot Quantification:

• Standardized loading: Equal protein loading (10-20 μg) confirmed by total protein stains or housekeeping proteins

• Linear dynamic range: Ensure detection falls within the linear range of the assay through preliminary experiments

• Normalization strategy: Use total protein normalization (preferred) or verified housekeeping proteins that don't change with your experimental conditions

• Technical replicates: Minimum three technical replicates per biological sample

• Densitometry analysis: Use software like ImageJ, quantifying band intensity minus background

• Statistical analysis: Apply appropriate statistical tests based on experimental design

Flow Cytometry Quantification (for SOX11):

• Gating strategy: Define positive populations based on FMO (fluorescence minus one) controls

• Mean fluorescence intensity (MFI): Measure as quantitative indicator of expression level

• Calibration beads: Use for converting MFI to absolute molecules of equivalent soluble fluorochrome (MESF)

• Standardization: Include calibration controls across experiments

Immunohistochemistry Quantification (for SETD1B):

• Standardized staining: Use automated staining platforms where possible

• Digital pathology approach: Whole slide scanning with image analysis software

• Scoring system: Develop based on staining intensity and percentage of positive cells

• Region selection: Analyze multiple representative fields (at least 5-10)

• Blinded analysis: Have samples scored by individuals blinded to experimental conditions

Data Presentation:

• Present data as fold change relative to control conditions

• Include representative images alongside quantitative graphs

• Report both means and measures of variability (standard deviation or standard error)

• Include sufficient sample sizes (minimum n=3 biological replicates) for statistical validity

What are the emerging applications of SET11 antibodies in single-cell analysis and spatial transcriptomics?

SET11 antibodies are increasingly being integrated into cutting-edge single-cell and spatial analysis techniques, offering unprecedented insights into heterogeneous cell populations and spatial contexts:

Single-Cell Protein Analysis:

• Mass cytometry (CyTOF) using metal-conjugated SET11 antibodies enables simultaneous detection of SOX11 or SETD1B alongside dozens of other proteins at single-cell resolution

• CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) can pair SET11 protein detection with transcriptomic profiling in the same cells

• These approaches are particularly valuable for studying SOX11 in heterogeneous neural progenitor populations or SETD1B in diverse hematopoietic cell lineages

Spatial Transcriptomics Applications:

• Multiplexed immunofluorescence with SET11 antibodies combined with RNA in situ hybridization enables correlation between protein expression and transcriptional states in tissue context

• For SETD1B studies, co-localization with H3K4 methylation marks and target genes in tissue sections provides insights into functional epigenetic regulation in the native microenvironment

• Digital spatial profiling platforms allow quantitative analysis of SOX11 or SETD1B protein expression across tissue regions with detailed spatial resolution

Methodological Considerations:

• Antibody validation for these specialized applications is essential, including specificity testing in multiplexed formats

• Signal amplification strategies may be necessary for detecting low-abundance proteins like SETD1B

• Custom conjugation protocols for SET11 antibodies need optimization for each platform

• Computational analysis pipelines must be developed to integrate protein expression data with other single-cell modalities

These emerging applications are particularly promising for understanding the roles of SOX11 in neural development and SETD1B in chromatin regulation within complex tissues and heterogeneous cell populations .

How do polyclonal and monoclonal SET11 antibodies compare in different research applications?

The choice between polyclonal and monoclonal SET11 antibodies significantly impacts experimental outcomes. These antibody types offer distinct advantages and limitations across applications:

Western Blotting:

• Monoclonal SOX11 antibody provides high specificity with clean background, recognizing a single epitope. This results in precise bands at the expected molecular weight as demonstrated in human fetal brain, SH-SY5Y, and Y79 cell lysates .

• Polyclonal SETD1B antibody may detect multiple epitopes, potentially increasing sensitivity but sometimes leading to additional bands. Careful optimization of dilution (starting at 1 μg/ml) is required .

Immunoprecipitation:

• Monoclonal SOX11 antibody delivers consistent performance across experiments with high specificity for the target protein.

• Polyclonal SETD1B antibody has demonstrated effectiveness at 10 μg/mg of lysate, potentially capturing more protein by recognizing multiple epitopes .

Immunohistochemistry:

• Polyclonal SETD1B antibody can be advantageous in fixed tissues where some epitopes may be masked, as it recognizes multiple binding sites.

• Monoclonal SOX11 antibody provides more consistent staining patterns across different batches and typically requires less optimization.

Flow Cytometry:

• Monoclonal SOX11 antibody has been validated for intracellular flow cytometry applications with well-defined positive populations .

• Polyclonal antibodies generally require more extensive blocking and washing steps to reduce background.

Reproducibility Considerations:

• Monoclonal antibodies offer superior batch-to-batch consistency, critical for longitudinal studies.

• Polyclonal antibodies may vary between lots, requiring validation when switching batches.

The selection should be guided by the specific research application, with monoclonal antibodies preferred for precise quantification and polyclonal antibodies sometimes advantageous for applications where sensitivity is paramount .

What factors should researchers consider when selecting the appropriate SET11 antibody for specific experimental approaches?

Selecting the optimal SET11 antibody requires systematic evaluation of multiple factors aligned with experimental objectives:

Experimental Application:

• For high-resolution microscopy, select antibodies validated for immunofluorescence with low background

• For protein-protein interaction studies, choose antibodies that don't interfere with interaction domains

• For ChIP applications, select antibodies validated to work in crosslinked chromatin environments

Epitope Accessibility:

• Consider whether target epitopes might be masked in your experimental system

• For SETD1B in protein complexes, ensure the antibody recognizes accessible regions

• For denatured applications (Western blot), linear epitope recognition is sufficient

• For native applications (IP, ChIP), conformation-sensitive epitope recognition may be critical

Validation Standards:

• Prioritize antibodies with validation in multiple applications

• Check citation records for successful use in applications similar to yours

• For SOX11 antibody, EPR8191(2) has been cited in 8 publications, indicating reliability

• For SETD1B antibody, review the 3 citations for relevant applications

Species Reactivity:

• Match antibody species reactivity to your experimental model

• Cross-reactivity with other species should be experimentally confirmed

• Both antibodies discussed here react with human samples, but other species may require validation

Technical Specifications:

• Consider clonality (monoclonal vs. polyclonal) based on application needs

• Review recommended dilutions for your specific application

• Assess host species compatibility with your detection systems

• Evaluate conjugation needs (unconjugated vs. directly labeled)

A comprehensive selection matrix weighing these factors against experimental priorities will guide optimal antibody selection for your specific SET11 research applications .

How can researchers distinguish between true SET11 signal and artifacts in complex tissue samples?

Distinguishing genuine SET11 signal from artifacts in complex tissues requires rigorous controls and methodological considerations:

Essential Control Experiments:

• Negative controls:

  • Isotype-matched control antibodies processed identically to experimental samples

  • Tissues known not to express the target protein (negative tissue controls)

  • For SETD1B, include non-proliferating, terminally differentiated tissues as negative controls

• Positive controls:

  • Tissues with documented expression: fetal brain for SOX11 , ovarian carcinoma for SETD1B

  • Recombinant protein standards or overexpression systems

• Absorption controls:

  • Pre-incubate antibody with immunizing peptide to confirm specificity

  • Signal should disappear or significantly diminish in absorption controls

Signal Validation Strategies:

• Multi-method confirmation:

  • Validate findings with orthogonal techniques (e.g., IF, IHC, Western blot, RNA-seq)

  • Correlation between protein and mRNA expression provides additional confidence

• Signal characteristics assessment:

  • SOX11 should show predominantly nuclear localization consistent with its transcription factor function

  • SETD1B should also display nuclear localization patterns consistent with its histone methyltransferase activity

  • Unexpected subcellular localization warrants additional validation

• Titration experiments:

  • Perform antibody dilution series to identify optimal signal-to-noise ratio

  • True signal should decrease proportionally with antibody dilution, while artifacts often don't follow this pattern

• Technical approaches:

  • Autofluorescence control (unstained section) for fluorescence microscopy

  • Antigen retrieval optimization to balance between signal recovery and artifact introduction

  • Multiple fixation methods comparison to rule out fixation artifacts

• Genetic validation:

  • When possible, tissues from knockout/knockdown models provide definitive validation

  • CRISPR-edited cell lines can serve as powerful controls

These comprehensive validation approaches ensure that observed SET11 signals in complex tissues accurately represent biological reality rather than technical artifacts .

What are the current limitations in SET11 antibody technology, and how might they be addressed in future research?

Current SET11 antibody technologies face several limitations that impact research reliability and applications. These challenges and potential future solutions include:

Current Limitations:

• Epitope accessibility issues: Both SOX11 and SETD1B proteins function within large macromolecular complexes, potentially masking epitopes. SETD1B, as a histone methyltransferase, is particularly challenging as it functions within chromatin remodeling complexes .

• Specificity challenges: The SOX family contains multiple members with structural similarity, creating potential cross-reactivity issues. Similarly, SETD1B shares domains with other SET domain-containing proteins .

• Post-translational modification detection: Current antibodies may not distinguish between different post-translationally modified forms of SET11 proteins, limiting functional studies.

• Sensitivity limitations: Detection of low-abundance proteins, particularly in certain cell types, remains challenging.

• Batch-to-batch variation: Particularly for polyclonal antibodies like the SETD1B antibody, variation between production lots affects experimental reproducibility .

Future Directions and Solutions:

• Recombinant antibody technology: Expanding the use of recombinant monoclonal antibodies, as exemplified by the SOX11 antibody (EPR8191(2)), to improve reproducibility and specificity .

• PTM-specific antibodies: Development of antibodies specifically recognizing post-translationally modified forms of SET11 proteins to enhance functional studies.

• Nanobodies and single-domain antibodies: Smaller antibody formats may access epitopes hidden in protein complexes more effectively.

• Proximity labeling approaches: Combining antibodies with enzymatic tags for proximity labeling could enhance detection of protein interactions in native complexes.

• Antibody engineering: Affinity maturation and humanization of research antibodies could improve performance characteristics.

• Machine learning for epitope selection: Computational approaches to identify unique epitopes could enhance antibody specificity .

• Standardized validation protocols: Development of field-wide standards for antibody validation would improve reliability and reproducibility .

These advances would address current limitations in SET11 antibody technology, ultimately improving research outcomes and expanding application possibilities .

How does antibody polyreactivity impact SET11 antibody performance, and what strategies can mitigate these effects?

Antibody polyreactivity—the non-specific binding of antibodies to multiple unrelated antigens—presents significant challenges for SET11 antibody applications. Understanding and mitigating these effects is crucial for reliable research outcomes:

Impact of Polyreactivity on SET11 Antibody Performance:

• Reduced signal-to-noise ratio: Polyreactive antibodies bind non-specifically to multiple targets, increasing background and obscuring genuine signals. This is particularly problematic in complex tissue samples .

• False positive results: Non-specific binding can lead to misinterpretation of experimental results, especially in co-localization studies or protein interaction analyses.

• Inconsistent quantification: Polyreactivity introduces variability in quantitative analyses, compromising comparisons across experimental conditions.

• Variable performance across applications: An antibody with acceptable specificity in Western blotting may show problematic polyreactivity in immunoprecipitation or immunohistochemistry due to differences in protein conformation and experimental conditions .

Molecular Basis of Polyreactivity:

Recent research indicates that human antibody polyreactivity is primarily mediated by the heavy chain variable regions, with high positive charge and hydrophobicity in the complementarity-determining regions (CDRs) being key contributors . For SET11 antibodies, these characteristics should be evaluated during selection and validation.

Mitigation Strategies:

• Stringent blocking protocols:

  • Use multi-component blocking solutions (combinations of BSA, normal serum, and non-fat milk)

  • Include carrier proteins (0.1-0.5% gelatin) in antibody diluents

  • Consider non-mammalian protein blockers for mammalian samples

• Pre-adsorption techniques:

  • Pre-incubate antibodies with tissues or cell lysates from negative control samples

  • For recombinant antibodies like SOX11 (EPR8191(2)), pre-adsorption may be less necessary but still beneficial in high-background tissues

• Buffer optimization:

  • Include mild detergents (0.1-0.3% Triton X-100) to reduce hydrophobic interactions

  • Adjust salt concentration (150-500 mM NaCl) to disrupt ionic interactions

  • Optimize pH conditions to minimize non-specific binding

• Application-specific approaches:

  • For IP: Increase pre-clearing steps with protein A/G beads and non-specific IgG

  • For IHC: Implement dual antigen retrieval strategies and optimize antibody concentration

  • For WB: Use PVDF membranes for SOX11 detection and nitrocellulose for SETD1B detection

• Validation with multiple detection methods:

  • Confirm findings using orthogonal techniques with different potential polyreactivity profiles

  • Validate with genetic models (knockdown/knockout) where available

Implementing these strategies can significantly reduce the impact of polyreactivity, improving the reliability and reproducibility of SET11 antibody-based research .

What are the most promising emerging applications for SET11 antibodies in epigenetic and transcriptional regulation research?

SET11 antibodies are positioned at the forefront of several emerging research areas in epigenetics and transcriptional regulation. These promising applications leverage advances in technology and biological understanding:

Multi-omic Integration Approaches:

• CUT&Tag with SET11 antibodies: SETD1B antibodies can be adapted for Cleavage Under Targets and Tagmentation (CUT&Tag) protocols, providing higher resolution and lower background than traditional ChIP-seq. This approach enables genome-wide mapping of SETD1B binding sites with reduced input material .

• Sequential ChIP (re-ChIP): Using SOX11 and SETD1B antibodies in sequential immunoprecipitation to identify genomic loci where both factors co-localize, revealing potential cooperative regulatory mechanisms between transcription factors and chromatin modifiers .

• Spatial epigenomics: Combining SETD1B antibody-based chromatin studies with spatial transcriptomics to correlate chromatin states with gene expression in a tissue context.

Dynamic Regulatory Studies:

• Live-cell chromatin dynamics: Developing SET11 antibody-derived nanobodies fused to fluorescent proteins for live imaging of chromatin modifier dynamics without disrupting cellular function.

• Temporal epigenomic profiling: Using SETD1B antibodies to track changes in histone methyltransferase activity through developmental transitions or disease progression.

• Single-molecule tracking: Adapting SET11 antibody fragments for tracking individual molecules of SOX11 or SETD1B in living cells to understand dynamics and residence times on chromatin.

Therapeutic Development Applications:

• Target validation: Using highly specific SET11 antibodies to validate the role of these proteins in disease contexts, particularly neurodevelopmental disorders for SOX11 and certain cancers for SETD1B.

• Antibody-guided epigenetic editing: Conjugating SETD1B antibodies with catalytic domains to direct epigenetic modifications to specific genomic loci.

• Degrader development: SET11 antibodies can help validate novel degrader therapeutics (PROTACs) targeting these proteins by confirming mechanism of action.

Single-Cell Applications:

• Single-cell CUT&Tag: Adapting SETD1B antibodies for single-cell epigenomic profiling to understand cell-to-cell heterogeneity in histone methylation patterns.

• Multi-modal single-cell analysis: Combining SET11 antibody-based protein detection with transcriptomics and epigenomics in the same cells to create comprehensive regulatory maps.

These emerging applications represent frontier areas where SET11 antibodies are enabling new biological insights, particularly in understanding the complex interplay between transcription factors like SOX11 and chromatin modifiers like SETD1B in development and disease .